Yale Analysis Finds Lifestyle and Prescriptions Lower Epigenetic Age More Reliably Than Supplements

September 17, 2026

•

Healthy Aging

Share this post

A Yale led study published in Nature Medicine in August 2026 evaluated 51 longitudinal human intervention studies to determine whether epigenetic aging biomarkers respond consistently to longevity treatments. The researchers assembled this data to test how well these biomarkers detect biological changes following intervention.

The Study Methodology

A research team led by Yale University sought to evaluate whether specific biological markers respond reliably to longevity treatments. The researchers assembled data from 51 longitudinal human intervention studies. They analyzed blood based DNA methylation measurements to build a comprehensive picture of epigenetic changes. The pooled dataset included 3,128 DNA methylation samples, providing a substantial foundation for the analysis.

The 51 longitudinal studies provided a wide cross section of health backgrounds, age ranges and metabolic conditions. By tracking these blood based markers over time, the team sought to identify measurable biological shifts following specific longevity protocols. The interventions tested in the underlying studies spanned ordinary behaviors, prescription medicines, biologics, procedures and supplements. These included exercise, Mediterranean and plant based diets, calorie restriction and intermittent fasting.

Medical and surgical interventions featured metformin, semaglutide and rapamycin. Anti TNF therapies, bariatric surgery and hyperbaric oxygen therapy were also included. The inclusion of smoking cessation and dietary supplements highlighted how longevity research now spans multiple treatment categories. This broad sample allowed researchers to observe how different interventions perform across distinct treatment approaches.

To track the effects of these interventions, the study examined 16 widely used epigenetic clocks. They compared these clocks alongside more than 90 additional DNA methylation biomarkers. Yale describes the total as 111 biomarkers evaluated in the comprehensive framework. This extensive comparison allowed the researchers to see which specific tests actually respond when a patient undergoes a health intervention.

Primary Aging Findings

The central finding was that lifestyle interventions consistently moved epigenetic aging measures in a favorable direction. Combinations of healthy eating and regular physical exercise consistently produced positive changes across the analyzed aging measures. Yale specifically identified Mediterranean, low carbohydrate and low fat dietary patterns alongside exercise as relevant lifestyle interventions in the underlying studies. This reinforces the value of foundational habits over isolated wellness trends.

Pharmacological interventions produced the largest average reductions in epigenetic age in the analysis. The named prescription therapies included metformin, semaglutide and anti TNF therapies. Study coverage reported significant reductions across all 16 clocks for these medication categories. Prescription therapies like modern weight management medications showed measurable biological impacts that outpaced other tested categories.

The findings regarding dietary supplements were substantially less consistent than the medication and lifestyle results. The reviewed article does not identify a single over the counter supplement that reliably lowered epigenetic age across the full analysis. The supplement findings were limited and inconclusive, which is why evaluating the actual evidence for healthy aging pills remains a practical necessity. Broad supplement stacks simply did not automatically produce a favorable biological response in this pooled data.

A separate summary of the study by MedicalDaily detailed the statistical breakdown of the tested interventions. Nineteen of the 51 interventions significantly reduced epigenetic age before multiple testing correction. Thirteen remained significant after that correction was applied, while five significantly increased epigenetic age. The remaining 26 showed no significant effect in either direction, showing that over half of the tested interventions lacked a statistically significant favorable movement.

The study results also suggest that not all epigenetic clocks measure the same aspect of aging or respond equally to interventions. Biomarkers designed to estimate the pace of aging or predict mortality appeared more responsive across interventions than some older options. NutraIngredients identified DunedinPACE, PCGrimAge and GrimAgeV2 among the newer or reliability optimized measures that responded more consistently. Measures like PCPhenoAge and SystemsAge also outperformed older chronological age clocks.

DunedinPACE functions like a speedometer that estimates the current pace of biological aging rather than absolute age. The newer reliability optimized measures showed greater consistency across multiple interventions. This distinction is critical because older clocks were primarily trained to estimate chronological age, making them less sensitive to short term lifestyle adjustments. A favorable result on one aging clock should not automatically be treated as equivalent to a favorable result on every other clock.

Practical Lifestyle Focus

For men in their late 40s and beyond, the most defensible takeaway is to treat diet and regular exercise as the foundation of healthy aging. The study found consistent favorable movement from lifestyle interventions, while supplement results were variable and limited. A practical lifestyle emphasis involves a sustainable dietary pattern combined with regular physical activity. The available evidence supports prioritizing these repeatable habits over expensive products whose effects on epigenetic age remain uncertain.

When men return to training after a long break, they often look for rapid solutions or quick fixes to regain lost physical capacity. The findings from this analysis strongly support prioritizing consistency and sustainable habits over novel but unproven interventions. The available evidence backs a pragmatic approach focused on repeatable daily actions. Men should not substitute an epigenetic age score for functional outcomes like maintaining physical capacity.

The study itself did not prove that clock changes directly translate into preserved physical function or longer healthspan. Tracking real world outcomes like strength, walking capacity, blood pressure and sleep provides a clearer picture of daily capability. Laboratory biomarkers should be viewed alongside these functional metrics rather than treated as the sole outcome. A biological age test is a data point rather than a definitive measure of physical independence.

Prescription medications may be valuable when they address an actual medical problem such as diabetes, obesity or inflammatory disease. Men should discuss these treatments with a qualified clinician based on clear diagnoses and established indications. Men often face confusion over shifting hormone levels and related metabolic shifts when trying to address aging symptoms. They should use medical guidance rather than relying on this study to self prescribe an anti aging drug.

Limitations and Context

The Yale summary explicitly frames the work as an assessment of biomarker responsiveness rather than proof that any individual intervention extends lifespan. A lower epigenetic age reading is not the same as proof of slower biological aging. It is not yet established from this analysis whether a favorable change predicts preserved cognition, fewer diseases or a longer period of healthy independence. The clinical meaning of a short term clock change remains unresolved in longevity research.

Some intervention studies involved people with underlying diseases. An improved epigenetic measure in these patients may partly reflect an improvement in their specific disease state rather than a direct slowing of aging itself. A drug that improves glucose control, body weight or inflammation may change methylation related markers without proving a general anti aging effect. The categories should not be interpreted as a blanket ranking of all exercise, all diets or all prescription medicines.

The researchers pooled heterogeneous studies and evaluated biomarker responsiveness across interventions rather than establishing a universal treatment effect for every product. The researchers also noted that the supplement conclusion is mixed and insufficiently consistent rather than a blanket statement that all supplements are useless. A supplement may still have a role when correcting a documented vitamin or mineral deficiency. The pooled longevity evidence simply did not show a dependable overall effect on epigenetic aging for over the counter supplements.

The study does not establish that combining multiple drugs or supplements produces additive or superior effects. Whether combination strategies lower epigenetic age more effectively remains an open research question. The primary purpose was not to prove that any particular treatment extends human lifespan, but to test which biomarkers appear responsive enough for future trials. Responsiveness is only one requirement for a useful clinical endpoint, as prognostic validity and biological reliability still require further evaluation.

Changing Aging Strategies

Lead author Raghav Sehgal said that the field previously lacked a rigorous framework for determining which biological aging biomarkers are sufficiently prognostic, responsive and reliable for clinical trials. He described TranslAGE, the study’s open framework, as a roadmap for selecting biomarkers that consistently detect biological changes following intervention. TranslAGE was created to let researchers compare more than 100 biomarkers across more than 50 putative longevity interventions.

Senior author Albert Higgins Chen noted that selecting the right biomarker is becoming as critical as selecting the intervention as longevity therapies move toward larger human trials. He said the framework is intended to reduce unnecessary multiple testing, false positive findings and publication bias in geroscience research. The study contributes to a broader shift in longevity research from asking whether a product is marketed for aging to asking whether a measurable biomarker responds reproducibly.

This research alters current best practices by confirming that foundational lifestyle habits and appropriate medical treatments deliver measurable biological responses, while speculative supplement stacks remain scientifically unproven for longevity.

How Everfitguys helps

Deciding which longevity interventions actually slow biological aging often leaves men guessing between foundational habits and heavily marketed over the counter supplements. Confusion about hormonal changes and testosterone claims frequently pushes men toward speculative anti aging stacks, but Everfitguys translates dense clinical biomarker research to help you prioritize proven metabolic therapies and lifestyle adjustments.

Read the research